Skip to contentT
TScan Therapeutics, Inc.
T
TCRXTScan Therapeutics, Inc. Q4 2024 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$665.00K$665.00Kderived−90.8% vs Q4 2023 Net Income-$35.81M-$35.81MderivedN/M vs Q4 2023 EPS, diluted—
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
TScan Therapeutics, Inc. · CIK 1783328 · Engraved from SEC EDGAR
Not derived. Share counts vary by quarter.
Operating Incomederived-$36,712,000N/M Operating Cash Flowderived-$27,412,000N/M Free Cash Flowderived-$28,300,000N/M Margins · derivedOperating margin-5520.6%−5224.4 pt vs Q4 2023
Net margin-5384.8%−5112.8 pt vs Q4 2023
ended Dec 31, 2024 · filed Mar 5, 2025 · 64 d after period end